## [1] "/cloud/project"
## [1] "Experiment 1" "Experiment1.txt"
## [3] "Experiment2.txt" "project.Rproj"
## [5] "rsconnect" "Template_formative.html"
## [7] "Template_formative.nb.html" "Template_formative.pdf"
## [9] "Template_formative.Rmd"
## [1] "control" "Pembrolizumab"
## [1] "1" "2" "3" "4" "5" "6" "7" "8" "9"
## [1] "control" "Pembrolizumab"
## Warning in stat_summary(fun = mean, geom = "point", shape = 4, size = 4, :
## Ignoring unknown parameters: `linewidth`
## Warning: The dot-dot notation (`..ymin..`) was deprecated in ggplot2 3.4.0.
## ℹ Please use `after_stat(ymin)` instead.
## This warning is displayed once every 8 hours.
## Call `lifecycle::last_lifecycle_warnings()` to see where this warning was
## generated.
## Warning: The `fatten` argument of `geom_boxplot()` is deprecated as of ggplot2 4.0.0.
## ℹ Please use the `median.linewidth` argument instead.
## This warning is displayed once every 8 hours.
## Call `lifecycle::last_lifecycle_warnings()` to see where this warning was
## generated.
###Fig 1: Testosterone expression of tumour epithelial cells in mice.
Intracellular testosterone levels were quantified by flow cytometry and
are shown in arbitrary units (a.u.) for control (n = 9) and
Pembrolizumab-treated (n = 9) groups. Data are presented as a
box-and-whisker plot: the line within the box represents the median, the
box shows the interquartile range (25th–75th percentile), and whiskers
indicate the minimum and maximum values. The mean ± SEM for each group
is as follows; (control: 1.01 ± 0.042; Pembrolizumab: 0.392 ± 0.053). An
unpaired two-tailed t-test was used to assess statistical significance,
revealing a significant reduction in testosterone expression in the
Pembrolizumab group (p<0.0001, threshold p < 0.05). Sample Size;
n=9.
## control Pembrolizumab
## Min. :0.790 Min. :0.2300
## 1st Qu.:0.990 1st Qu.:0.2700
## Median :1.050 Median :0.3400
## Mean :1.006 Mean :0.3922
## 3rd Qu.:1.080 3rd Qu.:0.5000
## Max. :1.150 Max. :0.6700
Research Hypothesis: Exposure to the anti-PD1 drug, Pembrolizumab, results in a reduction of testosterone expression in mouse tumour epithelial cells when compared to the untreated control.
H0: There is no significant difference in the means of the control and Pembrolizumab groups. H1: There is a significant difference between the means of the control and Pembrolizumab groups.”
Shapiro Wilk test and QQ plot show data follows normal distribution
## [1] "Control"
##
## Shapiro-Wilk normality test
##
## data: Data1$control
## W = 0.84333, p-value = 0.06289
## [1] "Pembrolizumab"
##
## Shapiro-Wilk normality test
##
## data: Data1$Pembrolizumab
## W = 0.88925, p-value = 0.196
## [1] "p value not significant. Data follows normal distribution"
## [1] "Unpaired two tailed t-test to test significance of difference"
##
## One Sample t-test
##
## data: Data1
## t = 8.6126, df = 17, p-value = 1.318e-07
## alternative hypothesis: true mean is not equal to 0
## 95 percent confidence interval:
## 0.5276829 0.8700949
## sample estimates:
## mean of x
## 0.6988889
## [1] "p value is significant. Enough evidence to reject the null hypothesis"
###AS PART OF THE 250 WORDS PLEASE ALSO STATE YOUR INTERPRETATION OF THE DATA
A box-and-whisker plot was used to visualize the spread and distribution of the data, which showed no outliers. Given the small sample size (n = 9 per group), the Shapiro Wilk test was applied to assess normality, an appropriate choice for small datasets. Both groups passed the normality test (control: p = 0.0629, Pembrolizumab: p = 0.196), indicating that the data do not significantly deviate from a normal distribution. The box plot depicts the median and interquartile range, while the standard error of the mean (SEM) provides an indication of the variability around the mean for each group. Non-overlapping boxes suggest a potential difference between the control and Pembrolizumab groups. However, formal statistical testing is required to confirm this observation. Given that the data are independent, continuous, and approximately normally distributed, an unpaired two-tailed t-test was employed to compare the groups. The test yielded a highly significant result (p < 0.0001), allowing rejection of the null hypothesis that Pembrolizumab significantly reduces testosterone expression when compared to the untreated control group. This finding supports the research hypothesis, demonstrating that treatment with Pembrolizumab significantly reduces testosterone expression in tumour epithelial cells of testicular cancer mouse models. Overall, visualising the data and statistical testing provides evidencse for a biologically meaningful decrease in testosterone levels following treatment. Further research and data with a greater sample size are required to solidify this conclusion. This approach appropriately balances the challenges of small sample size with the parametric assumptions required for the t-test.